

Montelukast Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 11/18/2016
4.2	05/02/2017	23015-00009	Date of first issue: 10/17/2014

SECTION 1. IDENTIFICATION

Product name : Montelukast Granules Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc

Address : 2000 Galloping Hill Road
Kenilworth - New Jersey - USA 1685

Telephone : 908-740-4000

Telefax : 908-735-1496

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION**GHS classification in accordance with 29 CFR 1910.1200**

Combustible dust

GHS label elements

Signal Word : Warning

Hazard Statements : If small particles are generated during further processing, handling or by other means, may form combustible dust concentrations in air.

Other hazards

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Hazardous ingredients

Chemical name	CAS-No.	Concentration (% w/w)
Montelukast	151767-02-1	≥ 0.1 - < 1

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical

Montelukast Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 11/18/2016
4.2	05/02/2017	23015-00009	Date of first issue: 10/17/2014

advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap.
Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : No special precautions are necessary for first aid responders.

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Montelukast Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 11/18/2016
4.2	05/02/2017	23015-00009	Date of first issue: 10/17/2014

- Personal precautions, protective equipment and emergency procedures : Follow safe handling advice and personal protective equipment recommendations.
- Environmental precautions : Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust. Handle in accordance with good industrial hygiene and safety practice. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers. Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types: Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**Ingredients with workplace control parameters**

Ingredients	CAS-No.	Value type	Control parame-	Basis
-------------	---------	------------	-----------------	-------

Montelukast Granules Formulation

Version 4.2 Revision Date: 05/02/2017 SDS Number: 23015-00009 Date of last issue: 11/18/2016
 Date of first issue: 10/17/2014

		(Form of exposure)	ters / Permissible concentration	
Montelukast	151767-02-1	TWA	50 µg/m ³ (OEB 3)	Merck
		Wipe limit	500 µg/100 cm ²	Merck

Engineering measures : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection
Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures : Ensure that eye flushing systems and safety showers are located close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment,

Montelukast Granules Formulation

Version 4.2	Revision Date: 05/02/2017	SDS Number: 23015-00009	Date of last issue: 11/18/2016 Date of first issue: 10/17/2014
----------------	------------------------------	----------------------------	---

appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Color	:	No data available
Odor	:	No information available.
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	No data available

Montelukast Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 11/18/2016
4.2	05/02/2017	23015-00009	Date of first issue: 10/17/2014

Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Dust can form an explosive mixture in air. Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION**Information on likely routes of exposure**

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Ingredients:**Montelukast:**

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg LD50 (Mouse): > 5,000 mg/kg
---------------------	---	--

Acute inhalation toxicity	:	Remarks: No data available
---------------------------	---	----------------------------

Acute dermal toxicity	:	Remarks: No data available
-----------------------	---	----------------------------

Skin corrosion/irritation

Not classified based on available information.

Ingredients:**Montelukast:**

Species: Rabbit

Montelukast Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 11/18/2016
4.2	05/02/2017	23015-00009	Date of first issue: 10/17/2014

Result: Mild skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Ingredients:**Montelukast:**

Species: Rabbit

Result: Severe irritation

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Ingredients:**Montelukast:**

Remarks: No data available

Germ cell mutagenicity

Not classified based on available information.

Product:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	:	Test Type: In vitro mammalian cell gene mutation test Species: Chinese hamster fibroblasts Result: negative
	:	Test Type: Chromosomal aberration Species: Chinese hamster ovary cells Result: negative
	:	Test Type: Alkaline elution assay Species: rat hepatocytes Result: negative
Genotoxicity in vivo	:	Test Type: Chromosomal aberration Species: Mouse Cell type: Bone marrow Application Route: Oral Result: negative

Ingredients:**Montelukast:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
-----------------------	---	--

Montelukast Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 11/18/2016
4.2	05/02/2017	23015-00009	Date of first issue: 10/17/2014

- : Test Type: In vitro mammalian cell gene mutation test
Species: Chinese hamster fibroblasts
Result: negative
- : Test Type: Chromosomal aberration
Species: Chinese hamster ovary cells
Result: negative
- : Test Type: Alkaline elution assay
Species: rat hepatocytes
Result: negative
- Genotoxicity in vivo : Test Type: Chromosomal aberration
Species: Mouse
Cell type: Bone marrow
Application Route: Oral
Result: negative

Carcinogenicity

Not classified based on available information.

Product:

Species: Rat
Application Route: Oral
Exposure time: 2 Years
Dose: 200 mg/kg body weight
Result: negative

Species: Mouse
Application Route: Oral
Exposure time: 92 weeks
Dose: 100 mg/kg body weight
Result: negative

Ingredients:**Montelukast:**

Species: Rat
Application Route: Oral
Exposure time: 2 Years
Result: negative

Species: Mouse
Application Route: Oral
Exposure time: 92 weeks
Result: negative

IARC

No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA

No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

Montelukast Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 11/18/2016
4.2	05/02/2017	23015-00009	Date of first issue: 10/17/2014

NTP

No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified based on available information.

Product:

Effects on fertility : Test Type: Fertility
Species: Rat, male
Application Route: Oral
Fertility: NOAEL Parent: 800 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Test Type: Fertility
Species: Rat, female
Application Route: Oral
Fertility: LOAEL Parent: 200 mg/kg body weight
Symptoms: Reduced fertility

Effects on fetal development : Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL F1: 400 mg/kg body weight
Result: No teratogenic effects.

Test Type: Development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL F1: 300 mg/kg body weight
Result: No teratogenic effects.

Ingredients:**Montelukast:**

Effects on fertility : Test Type: Fertility
Species: Rat, male
Application Route: Oral
Fertility: NOAEL: 800 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Test Type: Fertility
Species: Rat, female
Application Route: Oral
Fertility: LOAEL: 200 mg/kg body weight
Symptoms: Reduced fertility

Effects on fetal development : Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 400 mg/kg body weight
Result: No teratogenic effects.

Montelukast Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 11/18/2016
4.2	05/02/2017	23015-00009	Date of first issue: 10/17/2014

Test Type: Development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 300 mg/kg body weight
Result: No teratogenic effects.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.

Repeated dose toxicity**Ingredients:****Montelukast:**

Species: Monkey, male and female
NOAEL: 150 - 300 mg/kg
Application Route: Oral
Exposure time: 53 Weeks
Remarks: No significant adverse effects were reported

Species: Rat
NOAEL: 50 mg/kg
Application Route: Oral
Exposure time: 53 Weeks
Remarks: No significant adverse effects were reported

Species: Mouse
NOAEL: 50 mg/kg
Application Route: Oral
Exposure time: 14 Weeks
Remarks: No significant adverse effects were reported

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Product:**

Skin contact	:	Remarks: May irritate skin.
Eye contact	:	Symptoms: Severe irritation
Ingestion	:	Symptoms: upper respiratory tract infection, pharyngitis, Headache, Cough, Abdominal pain, Diarrhea, Fever

Ingredients:**Montelukast:**

Skin contact	:	Remarks: May irritate skin.
Eye contact	:	Symptoms: Severe irritation

Montelukast Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 11/18/2016
4.2	05/02/2017	23015-00009	Date of first issue: 10/17/2014

Ingestion : Symptoms: upper respiratory tract infection, pharyngitis, Headache, Cough, Abdominal pain, Diarrhea, Fever

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Ingredients:****Montelukast:**

Toxicity to fish	: LC50 (Pimephales promelas (fathead minnow)): > 0.0778 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 Remarks: No toxicity at the limit of solubility.
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): > 0.0675 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: No toxicity at the limit of solubility.
Toxicity to algae	: NOEC (Pseudokirchneriella subcapitata (green algae)): 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility. EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility.
Toxicity to fish (Chronic toxicity)	: NOEC (Pimephales promelas (fathead minnow)): 0.073 mg/l Exposure time: 32 d Method: OECD Test Guideline 210 Remarks: No toxicity at the limit of solubility. NOEC (Cyprinodon variegatus (sheepshead minnow)): 0.0816 mg/l Exposure time: 7 d Remarks: No toxicity at the limit of solubility.
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC (Daphnia magna (Water flea)): 0.23 mg/l Exposure time: 21 d Remarks: No toxicity at the limit of solubility.
Toxicity to microorganisms	: EC50 (Natural microorganism): > 100 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 Remarks: No toxicity at the limit of solubility.

Montelukast Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 11/18/2016
4.2	05/02/2017	23015-00009	Date of first issue: 10/17/2014

Persistence and degradability**Ingredients:****Montelukast:**

Biodegradability : Result: not rapidly degradable
Biodegradation: 0 %
Exposure time: 28 d

Stability in water : Hydrolysis: 50 %(21.7 h)

Bioaccumulative potential**Ingredients:****Montelukast:**

Partition coefficient: n-octanol/water : log Pow: > 4.3

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation**49 CFR**

Not regulated as a dangerous good

Montelukast Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 11/18/2016
4.2	05/02/2017	23015-00009	Date of first issue: 10/17/2014

SECTION 15. REGULATORY INFORMATION**EPCRA - Emergency Planning and Community Right-to-Know****CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Fire Hazard

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations**Pennsylvania Right To Know**

D-mannitol

69-65-8

California Prop. 65

This product does not contain any chemicals known to the State of California to cause cancer, birth, or any other reproductive defects.

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined


Montelukast Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 11/18/2016
4.2	05/02/2017	23015-00009	Date of first issue: 10/17/2014

SECTION 16. OTHER INFORMATION

Further information

NFPA:



HMIS® IV:

HEALTH	/	0
FLAMMABILITY		3
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "/" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG -

Montelukast Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 11/18/2016
4.2	05/02/2017	23015-00009	Date of first issue: 10/17/2014

United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 05/02/2017

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8